Hyperdiploid (47-50) acute lymphoblastic leukemia in children

Area of Science:

• Pediatric Oncology
• Cytogenetics
• Hematologic Malignancies

Background:

• Hyperdiploidy (47-50 chromosomes) is a common cytogenetic subgroup in childhood acute lymphoblastic leukemia (ALL).
• This specific ploidy group has been less characterized compared to other ALL subtypes.
• Understanding its unique genetic features and prognostic implications is crucial for treatment stratification.

Purpose of the Study:

• To characterize the numerical and structural chromosomal abnormalities in childhood ALL with hyperdiploidy (47-50).
• To evaluate the impact of these chromosomal changes and translocations on event-free survival (EFS).
• To compare treatment outcomes between historical and contemporary chemotherapy regimens for this ALL subgroup.

Main Methods:

• Karyotype analysis of 598 newly diagnosed childhood ALL cases.
• Identification of numerical abnormalities (e.g., +21, +X, +8, +10) and structural abnormalities (e.g., 1q, 6q, 12p, 19p).
• Statistical analysis of EFS based on chromosomal features and treatment intensity using logrank test.

Main Results:

• 86 cases (14.4%) exhibited hyperdiploidy (47-50).
• Frequent numerical gains included +21, +X, +8, +10; common structural changes involved 1q, 6q, 12p, 19p.
• No significant difference in EFS was observed based on translocations or specific chromosome gains (P > .05).
• Patients receiving contemporary multiagent chemotherapy had significantly better 4-year EFS (75%) compared to historical less intensive therapy (41%) (P = .006).

Conclusions:

• Hyperdiploidy (47-50) in childhood ALL is characterized by specific numerical and structural chromosomal aberrations.
• The presence of translocations or specific chromosome gains does not significantly impact EFS in this subgroup.
• Modern, intensive chemotherapy significantly improves outcomes for children with hyperdiploid (47-50) ALL, challenging previous notions of an adverse prognosis.